xpressjilo.blogg.se - Xofigo prostate cancer

#Xofigo prostate cancer trial#

Bone scan (to assess bony metastases tracer avidity).

What Initial Investigations Are Needed Before Beginning Treatment With Radium-223 (Xofigo)?

Bone scan showing poor bony lesion tracer avidityĭiscussion with our physician regarding the potential risks and benefits of therapy will be required before commencing treatment.

Uncontrolled intercurrent illness or poor ECOG status.

Recent radiotherapy (6 weeks) or concurrent chemotherapy.

Impaired marrow function (platelet < 50 x 109/L, Hb < 100 g/L, absolute neutrophil count < 1.5 x 109/L).

Concurrent Abiraterone acetate, increased risk of fractures and mortality shown.

What Are the Contraindications to Radium-223 (Xofigo)? The typical patients who may benefit are those with Metastatic Castrate Resistant Prostate Cancer (mCRPC) with bony metastases and no visceral metastases and biochemical progression. Who Will Benefit From Treatment With Radium-223 (Xofigo)? Other side effects include vomiting, diarrhoea, and generalised weakness, but these are typically temporary and self-limiting. However, the risk of myelosuppression is higher and more refractory in heavily pre-treated patients and those with extensive bony marrow disease. Such haematological suppression is typically temporary. More severe myelosuppression (Grade 3-4) occurs in approximately 5-10% of patients. Low-grade myelosuppression (Grade 1-2) is common. The most common side effect is haematological suppression (lowered red blood cells, white blood cells, and platelets).

Radium-223 (Xofigo) has a well-documented safety profile. What Are the Potential Side Effects of Radium-223 (Xofigo)? The PSA test is a blood test primarily used in the testing for prostate cancer.

#Xofigo prostate cancer trial#

This was demonstrated in a double-blind, randomised, placebo-controlled phase III clinical trial consisting of 921 patients with castrate-resistant prostate cancer with symptomatic bony metastases and no known visceral metastases (Alsympca trial).įollowing therapy, there was typically a mild-moderate response in PSA levels (50% producing a drop of more than 30%), while the drop-in ALP levels were typically more dramatic. Radium-223 (Xofigo) therapy is a therapeutic agent shown to extend overall survival in patients significantly. The therapy aims to control the bony metastases and reduce bony pain symptoms (if present). What Are the Expected Outcomes of Radium-223 Therapy (Xofigo)? Meaning that when injected, Radium-223 will circulate through the body and form complexes with bony mineral, Hydroxyapatite at the areas of increased bony turnover, such as bone metastases.Īs such, Radium-223 (Xofigo) radioactivity can uniquely target areas of sclerotic bony metastases, causing DNA damage to the cancer cells while relatively sparing normal bone due to its short radiation range. Radium-223 (Xofigo) is an alpha-emitting radioisotope that mimics calcium. How does Radium-223 Therapy (Xofigo) work? It is a radioactive, targeted therapy that involves two main areas of treatment – radioactive and tumour-targeted.Īs a radioactive pharmaceutical, Xofigo treats castrate-resistant prostate cancer, symptomatic bone metastases, and no known Visceral Metastatic Disease.

Xofigo is known to aid in the prevention of symptoms caused by the cancer. Radium 223 (Xofigo) is a medication used as a treatment against prostate cancer that has spread to a patient’s bones. What to Expect During Treatment With Radium-223 (Xofigo)?.What Initial Investigations Are Needed Before Beginning Treatment With Radium-223 (Xofigo)?.What Are the Contraindications to Radium-223 (Xofigo)?.

Who Will Benefit From Treatment With Radium-223 (Xofigo)?.What Are the Potential Side Effects of Radium-223 (Xofigo)?.What Are the Expected Outcomes of Radium-223 Therapy (Xofigo)?.How does Radium-223 Therapy (Xofigo) work?.